ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $5,116,000 | +1317.2% | 32,100 | +1069.4% | 0.14% | +1083.3% |
| Q2 2021 | $361,000 | -64.1% | 2,745 | -64.8% | 0.01% | -68.4% |
| Q1 2021 | $1,006,000 | -44.9% | 7,808 | -28.7% | 0.04% | -44.1% |
| Q4 2020 | $1,827,000 | -33.0% | 10,952 | -52.7% | 0.07% | -74.2% |
| Q1 2019 | $2,727,000 | – | 23,167 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |